JAK1 Inhibitor NS-229 Granted FDA Orphan Drug Designation to Treat Allergic Autoimmune Condition
April 25th 2025NS-229 is a Janus kinase 1 (JAK1) inhibitor being investigated in eosinophilic granulomatosis with polyangiitis, a rare autoimmune condition that can cause severe allergic and asthmatic symptoms through inflammation of nerve cells.
Read More
“We’ve Got to Get This Right From the Start”: Expert Discusses MDPNP Impacts on Pharmacies
April 23rd 2025Ronna Hauser, PharmD, senior vice president of policy and pharmacy affairs at NCPA, discussed concerns the association has with the implementation of the Medicare Drug Price Negotiation Plan
Watch